Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) - HC Wainwright boosted their FY2026 earnings per share estimates for Alpha Cognition in a research note issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.20) per share for the year, up from their prior forecast of ($1.27). HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Alpha Cognition's current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Alpha Cognition's Q4 2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at $0.10 EPS and FY2027 earnings at ($0.29) EPS.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last issued its earnings results on Wednesday, November 11th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). Alpha Cognition had a negative net margin of 147.26% and a negative return on equity of 52.80%. The firm had revenue of $7.78 million during the quarter, compared to analysts' expectations of $7.04 million.
Several other brokerages have also recently commented on ACOG. Wall Street Zen cut shares of Alpha Cognition from a "hold" rating to a "sell" rating in a research note on Saturday. B. Riley Financial started coverage on shares of Alpha Cognition in a research note on Thursday, August 20th. They issued a "buy" rating and a $21.00 price objective on the stock. Raymond James Financial set a $21.00 target price on shares of Alpha Cognition and gave the stock an "outperform" rating in a report on Thursday. Finally, Craig Hallum reissued a "buy" rating and set a $17.00 target price on shares of Alpha Cognition in a report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, Alpha Cognition has an average rating of "Buy" and an average target price of $18.20.
Check Out Our Latest Report on ACOG
Alpha Cognition Stock Performance
ACOG opened at $8.30 on Monday. Alpha Cognition has a 12-month low of $4.50 and a 12-month high of $10.14. The firm has a market capitalization of $180.77 million, a PE ratio of -6.06 and a beta of 2.32. The firm has a 50 day moving average of $8.74 and a two-hundred day moving average of $7.28.
Insider Activity at Alpha Cognition
In related news, Director Robert Wills bought 10,000 shares of the stock in a transaction dated Friday, August 21st. The shares were purchased at an average price of $9.62 per share, for a total transaction of $96,200.00. Following the completion of the purchase, the director directly owned 32,241 shares of the company's stock, valued at $310,158.42. This represents a 44.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.60% of the stock is owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Aristides Capital LLC boosted its position in Alpha Cognition by 1.4% in the 1st quarter. Aristides Capital LLC now owns 218,510 shares of the company's stock worth $1,200,000 after purchasing an additional 3,052 shares in the last quarter. Pekin Hardy Strauss Inc. acquired a new stake in shares of Alpha Cognition during the 3rd quarter worth approximately $210,000. Marshall Wace LLP acquired a new stake in shares of Alpha Cognition during the 3rd quarter worth approximately $449,000. ACT Capital Partners L.P. purchased a new position in shares of Alpha Cognition during the 3rd quarter valued at approximately $464,000. Finally, Opaleye Management Inc. increased its holdings in shares of Alpha Cognition by 13.0% during the 2nd quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company's stock valued at $20,905,000 after purchasing an additional 333,517 shares in the last quarter.
Alpha Cognition Company Profile
(
Get Free Report)
Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer's type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.